Notice: This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends AQXP vs. ALKS, AXSM, TGTX, PBH, BHC, PRGO, APLS, MRUS, FOLD, and EWTXShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Alkermes (ALKS), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Bausch Health Companies (BHC), Perrigo (PRGO), Apellis Pharmaceuticals (APLS), Merus (MRUS), Amicus Therapeutics (FOLD), and Edgewise Therapeutics (EWTX). These companies are all part of the "medical" sector. Aquinox Pharmaceuticals vs. Alkermes Axsome Therapeutics TG Therapeutics Prestige Consumer Healthcare Bausch Health Companies Perrigo Apellis Pharmaceuticals Merus Amicus Therapeutics Edgewise Therapeutics Aquinox Pharmaceuticals (NASDAQ:AQXP) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Do institutionals and insiders hold more shares of AQXP or ALKS? 71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor AQXP or ALKS? In the previous week, Alkermes had 7 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 7 mentions for Alkermes and 0 mentions for Aquinox Pharmaceuticals. Alkermes' average media sentiment score of 0.63 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Alkermes is being referred to more favorably in the news media. Company Overall Sentiment Aquinox Pharmaceuticals Neutral Alkermes Positive Does the MarketBeat Community prefer AQXP or ALKS? Alkermes received 398 more outperform votes than Aquinox Pharmaceuticals when rated by MarketBeat users. However, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 70.48% of users gave Alkermes an outperform vote. CompanyUnderperformOutperformAquinox PharmaceuticalsOutperform Votes29971.88% Underperform Votes11728.13% AlkermesOutperform Votes69770.48% Underperform Votes29229.52% Do analysts recommend AQXP or ALKS? Alkermes has a consensus target price of $34.90, indicating a potential upside of 31.25%. Given Alkermes' higher probable upside, analysts plainly believe Alkermes is more favorable than Aquinox Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquinox Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAlkermes 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, AQXP or ALKS? Aquinox Pharmaceuticals has a beta of -7.37, indicating that its stock price is 837% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Which has stronger valuation and earnings, AQXP or ALKS? Alkermes has higher revenue and earnings than Aquinox Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M62.15-$31.58MN/AN/AAlkermes$1.51B2.86$355.76M$1.9513.64 Is AQXP or ALKS more profitable? Alkermes has a net margin of 22.15% compared to Aquinox Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 24.92% beat Aquinox Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% Alkermes 22.15%24.92%14.55% SummaryAlkermes beats Aquinox Pharmaceuticals on 13 of the 15 factors compared between the two stocks. Ad Investing Daily626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trader has done over the past 8 years—closing 647 trades, with an unbelievable 97% win rate. Now, for the first time, he's breaking his silence and revealing his personal technique for success.Click here to watch our exclusive interview and uncover his personal technique Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55B$6.96B$5.22B$8.51BDividend YieldN/A7.94%5.06%4.17%P/E RatioN/A5.8992.8912.89Price / Sales62.15400.341,681.9389.91Price / CashN/A22.5833.8331.25Price / Book21.365.654.734.56Net Income-$31.58M$152.32M$116.42M$224.58M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$66.00+43.3%N/A+1,247.1%$1.55B$25M0.008Gap UpHigh Trading VolumeALKSAlkermes4.8975 of 5 stars$26.47+3.0%$34.90+31.8%+7.3%$4.28B$1.66B13.572,100Analyst UpgradeAXSMAxsome Therapeutics4.7921 of 5 stars$88.84-0.2%$124.64+40.3%+33.9%$4.22B$291.49M-13.65589Upcoming EarningsNews CoverageTGTXTG Therapeutics4.7793 of 5 stars$26.90+7.3%$36.33+35.1%+120.3%$4.16B$346.72M44.10290News CoveragePBHPrestige Consumer Healthcare4.6379 of 5 stars$74.05+0.4%$94.20+27.2%+23.9%$3.65B$1.13B18.11540Upcoming EarningsPositive NewsBHCBausch Health Companies3.8928 of 5 stars$9.78+6.3%$7.75-20.8%+22.3%$3.59B$9.20B-20.3720,270Earnings ReportPRGOPerrigo4.8598 of 5 stars$26.09+1.8%$37.00+41.8%-11.6%$3.50B$4.66B-28.369,140Upcoming EarningsDividend AnnouncementAPLSApellis Pharmaceuticals4.51 of 5 stars$27.98+2.6%$65.41+133.8%-39.0%$3.41B$628.79M-10.21702Analyst ForecastMRUSMerus1.9875 of 5 stars$50.30+0.7%$86.70+72.4%+105.9%$3.41B$43.95M-12.7337News CoverageFOLDAmicus Therapeutics4.3439 of 5 stars$11.47+0.4%$17.13+49.3%-2.2%$3.40B$399.36M-29.41480Upcoming EarningsEWTXEdgewise Therapeutics1.9899 of 5 stars$34.00+1.3%$35.60+4.7%+411.6%$3.19BN/A-21.9460Positive News Related Companies and Tools Related Companies ALKS Competitors AXSM Competitors TGTX Competitors PBH Competitors BHC Competitors PRGO Competitors APLS Competitors MRUS Competitors FOLD Competitors EWTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AQXP) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQXP Stock Alerts